PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 6, 2026Blood Advances0 citationsOpen Access

Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia: A Single Institution Experience Across Six Decades

View Full Paper
DODaniel J. OlivieriMOMegan OthusPVPhuong T Vo

Key Points

  • The study aims to evaluate the long-term outcomes and evolution of allogeneic transplantation for aplastic anemia over six decades.
  • Retrospective cohort analysis of 607 recipients of allogeneic transplantation for aplastic anemia.
  • Examination of temporal changes in conditioning regimens and GVHD prophylaxis.
  • Assessment of overall survival rates among different donor types.
  • Improved non-relapse mortality observed over the decades.
  • Reduced rates of graft-versus-host disease noted in recent years.
  • Overall survival rates have increased for HLA-matched related and unrelated donors.

Abstract

Since the introduction of allogeneic bone marrow transplantation (BMT) for aplastic anemia, major advances have included refinements in conditioning regimens, graft-versus-host disease (GVHD) prophylaxis, high-resolution human leukocyte antigen (HLA) typing, pre-transplant transfusion practices, and general supportive care. We present a comprehensive retrospective single-center cohort study of 607 children and adults who underwent allogeneic transplantation for aplastic anemia over six decades at a single BMT center. We highlight key temporal changes in conditioning for related donor transplants, GVHD prophylaxis, and HLA matching that correspond with improved non-relapse mortality, reduced GVHD rates, and better overall survival among HLA-matched related and unrelated donor transplants. This work provides a historical perspective on the evolution of BMT for aplastic anemia for HLA-matched related and unrelated donor recipients and identifies persistent barriers to curative therapy, including patient age and donor availability. Further studies are needed to clarify the role of anti-thymocyte globulin in conditioning regimens, improve GVHD prevention and management, and expand use of alternative donors.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Olivieri et al. (2026) studied this question.

synapsesocial.com/papers/698585cb8f7c464f230097e1https://doi.org/10.1182/bloodadvances.2025018548
Ask AI
Helpful
Bookmark
Share
View Full Paper